Mesoblast Ltd (MESO)
Mesoblast Ltd is an Australian regenerative medicine company whose depositary receipt is listed on NASDAQ under MESO. Through its subsidiaries, the issuer develops cell-based therapies built on its proprietary platform of mesenchymal lineage cells and maintains research and development activities across Australia, the United States, Singapore, and Switzerland. Its pipeline includes Remestemcel-L, which is in Phase III clinical testing for several inflammatory and other conditions, including steroid-refractory acute graft versus host disease, biologic-refractory inflammatory bowel disease, ulcerative colitis, Crohn’s disease, chronic heart failure, and chronic low back pain related to degenerative disc disease. The company is also advancing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy. Mesoblast has established collaborations with Tasly Pharmaceutical Group, JCR Pharmaceuticals, and Grünenthal to support selected therapy programs.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MESO
|
$13.60
|
-16.8% Downside
|
Fair
|
$35
|
114.2% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-22.4x
|
3.7x
|
32.3x
|
2.114 B
|
2.119 B
|
5.8%
|
64.1%
|
-9.8
|
—
|
64.3%
|
